within Pharmacolibrary.Drugs.ATC.A;

model A03FA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 6.5e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00268,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006166666666666667,
    Tlag           = 900,            
    Vdp             = 0.00435,
    k12             = 2.77,
    k21             = 2.77
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03FA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cisapride is a gastroprokinetic agent that was used primarily to treat gastroesophageal reflux disease (GERD) and other gastrointestinal motility disorders. It acts as a serotonin 5-HT4 receptor agonist, stimulating acetylcholine release at enteric neurons to enhance gut motility. Due to its ability to cause serious cardiac arrhythmias (QT prolongation, torsades de pointes), cisapride has been withdrawn or restricted in many countries and is no longer widely approved for use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers of both sexes receiving single oral doses of cisapride.</p><h4>References</h4><ol><li><p>LeGrange, SN, et al., &amp; Willard, MD (1997). Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. <i>Journal of the American Animal Hospital Association</i> 33(6) 517–523. DOI:<a href=\"https://doi.org/10.5326/15473317-33-6-517\">10.5326/15473317-33-6-517</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9358420/\">https://pubmed.ncbi.nlm.nih.gov/9358420</a></p></li><li><p>Bateman, DN (1986). The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. <i>European journal of clinical pharmacology</i> 30(2) 205–208. DOI:<a href=\"https://doi.org/10.1007/BF00614304\">10.1007/BF00614304</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3709647/\">https://pubmed.ncbi.nlm.nih.gov/3709647</a></p></li><li><p>Bailey, DG, et al., &amp; Spence, JD (1998). Grapefruit juice-drug interactions. <i>British journal of clinical pharmacology</i> 46(2) 101–110. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.1998.00764.x\">10.1046/j.1365-2125.1998.00764.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9723817/\">https://pubmed.ncbi.nlm.nih.gov/9723817</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03FA02;
